NewsRoom

Archives: Search / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015

2014201320122011201020092008

Feb 4, 2021
--Multiple Clinical Development Milestones Anticipated in 2021--
Jan 4, 2021
- Safety Review Committee approved Phase 1b expansion cohorts in study arm evaluating zandelisib in combination with zanubrutinib in various B-cell maligniancies -
Nov 10, 2020
--Expands Clinical Development of Zandelisib to New Indications and Earlier Lines of Treatment--
Sep 9, 2020
- Strong cash position of ~$183 million at start of fiscal year 2021 -
Jul 2, 2020
Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis
May 26, 2020
- Event scheduled for June 2, 2020 at 8am ET; featuring leading KOL Matthew Matasar, M.D. -